Synergistic cytotoxicity of topoisomerse I inhibitors with alkylating agents and etoposide in human brain tumor cell lines

Anti-Cancer Drugs

Volumn 9, Issue 7, 1998, Pages 641-652

  Janss, Anna J ^a   Cnaan, Avital ^a   Zhao, Huaqing ^a   Shpilsky, Arkady ^a   Levow, Cindy ^a   Sutton, Leslie ^a   Phillips, Peter C ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Brain tumor cell lines; Camptothecin; Cisplatin; Etoposide; Synergy; Topoisomerase I inhibitor

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ALKYLATING AGENT; CAMPTOTHECIN; CARMUSTINE; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; TOPOTECAN; 4-HYDROXYPEROXYCYCLOPHOSPHAMIDE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE; DRUG DERIVATIVE;

ARTICLE; BRAIN TUMOR; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MEDULLOBLASTOMA; PRIORITY JOURNAL; TUMOR CELL LINE; CELL CULTURE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; METABOLISM;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CAMPTOTHECIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ETOPOSIDE; HUMANS; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 0031595047     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199808000-00010     Document Type: Article

References (48)

1. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58: 351-75.
2. Wang JC. Interaction between DNA and Escherichia coli protein mu. J Mol Biol 1971; 55: 523-33.
3. Slichenmer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993; 85: 271-91.
4. Gottleib JA, Guaarino AM, Call JB. Preliminary pharmacolgic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 1970; 54: 461-70.
5. Armand JP, Ducreux M, Mahjoubi M, et al. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 1995; 31A: 1283-7.
6. Bunn PA, Jr. The treatment of non-small cell lung cancer current perspectives, controversies, and future directions. Semin Oncol 1994; 21: 49-59.
7. O'Reilly S, Rowinsky EK. The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue. Crit Rev Oncol-Hematol 1996; 24: 47-70.
8. Perez-Soler R, Glisson BS, Kane J, Lee J, Raber MN, Hong WK. Phase II study of topotecan in patients with non-small cell lung cancer (NSCLC) previously untreated. Proc Am Soc Clin Oncol 1994; 13: A1223.
9. Perez-Soler R, Glisson BS, Lee JS, et al. Phase D Study of topotecan in patients with small cell lung cancer (SCLC) refractory to etoposide. Proc Am Soc Clin Oncol 1995; 14: A1078.
10. Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol 1997; 8: 837-55.
11. Saltz LB, Schwartz GK, Ilson DH, Quan V, Kelsen DP. A phase II study of topotecan administered five times daily in patients with advanced gastric cancer. Am J Clin Oncol 1997; 20: 621-5.
12. Slichenmyer WJ, Donehower RC. Recent clinical advances with camptothecin analogues. Cancer Treat Res 1995; 78: 29-43.
13. Blaney SM, Phillips PC, Packer RJ, et al. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 1996; 78: 527-31.
14. Tubergen DG, Stewart CF, Pratt CB, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol/Oncol 1996; 18: 352-61.
15. Blaney SM, Cole DE, Balis FM, Godwin K, Poplack DG. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in non-human primates. Cancer Res 1993; 53: 725-7.
16. Ryan AJ, Squires S, Strutt HL, Johnson RT. Camptothecin cytotxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res 1991; 19: 3295-300.
17. Potmesil M. Camptothecins: from bench research to hosptal wards. Cancer Res 1994; 54: 1431-9.
18. Friedman HS, Houghton PJ. Treatment of central nervous system xenografts with camptothecins. Ann NY Acad Sci 1996; 803: 210-2.
19. Phillips PC, Kaufmann S, Catterall M, Covin OM. Schedule-dependent activity of topoisomerase I inhibitors in intracranial medulloblastoma and glioma xenografts. Clin Cancer Res 1998; in press.
20. Boscia RE, Korbut T, Holden SA, Ara G, Teicher BA. Interaction of topoisomerase I inhibitors with radiation in cis-diammmedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo. Int J Cancer 1993; 53: 118-23.
21. Kim JH, Kim SH, Kolozxvary A, Khil MS. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in invo by topotecan, an inhibitor of DNA topoisomerase I. Int J Radiat Oncol Biol Phys 1992; 22: 515-8.
22. Mattern MR, Hofman GA, McCabe FL, Johnson RK. Synergic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res 1991; 51: 5813-6.
23. Hennequin C, Giocanti N, Balosso J, Favaudon V. Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. Cancer Res 1994; 54: 1720-8.
24. Boothman DA, Wang M, Schea RA, Burrows HL, Strickfaden S, Owens JK. Posttreatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant human alignant melanoma cells. Int J Radiat Oncol Biol Phys 1992; 24: 939-48.
25. Chou T-C, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517-24.
26. Fukuda M, Nishio K, Kanzawa F, et al. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res 1996; 56: 789-93
27. Cheng M-F, Chatterjee S, Berger NA. Schedule dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res 1994; 6: 269-79.
28. Pei XH, Nakanishi Y, Takayama K, et al. Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anti-Cancer Drugs 1997; 8: 231-7.
29. Friedman HS, Oakes WJ, Bigner SH, Wikstrand CJ, Bigner DD. Medulloblastoma: tumor biological and clinical perspectives. J Neuro-Oncol 1991; 11: 1-15.
30. Bertrand R, O'Connor PM, Kerrigan D, Pommier Y Sequential administration of captothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human conlon carcinoma HT-29 cells. Eur J Cancer 1992; 28A: 743-8.
31. Rosbe KW, Brann TW, Holden SA, Teicher BA, III EF. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro. Cancer Chemother Pharmacol 1989; 25: 32-6.
32. Tallarida RJ. Statistical analysis of drug combinations for synergism. Pain 1992; 49: 93-7.
33. Berenbaum MC. What is Synergy? Pharmacol Rev 1989; 41: 93-141.
34. Chou T-C, Talalay P. Analysis of combined durg effects: a new look at a very old problem. Trends Pharm Sci 1983; 450-4.
35. Jacobsen PF, Jenkyn PF, Papadimitriou JM. Establisment of human medulloblastoma cell line and its heterotransplantation into nude mice. J Neuropathol Exp Neural 1985; 44: 472-85.
36. Berenbaum MC. Synergy, additivism and antagonism in immunosuppression: a critical review. Clin Exp Immunol 1977; 28: 1-18.
37. Geco WR, Lawrence DD. Assessment of the degree of drug interaction where the response variable is discrete Am Stat Ass Proc Biopharmaceut Sect 1989: 226-31.
38. Geco WR. Importance of the structural component of generalized non-linear models for joint drug action. Am Stat Ass Proc Biopharmaceut Sect 1989; 183-8.
39. Deen DF, Williams ME. Isobologram analysis of X-ray-BCNU interactions in vitro. Radiat Res 1979; 79: 483-91.
40. Kaufmann SH. Antagonism between camptothecin and Topoisomerase II-directed chemotherapeutic agents in a human leukeria cell line. Cancer Res 1991; 51: 1-9.
41. D'Arpa P, Beardmore C, Liu LF. Involvement of nucleic acid synthesis in cell killing mechnasims of topoisomerase poisons. Cancer Res 1990; 50: 6919-24.
42. Stahl M, Kasimir-Bauer S, Harstrick A. Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro. Anti-Cancer Drugs 1997; 8: 671-6.
43. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979; 5: 85-91.
44. Ng T-H, Hung HMJ, Chi GYH. A new statistical method for testing a combination therapy's superiority to both of its components. Am Stat Ass Proc Biopharmaceut Sect 1989: 60-5.
45. Hung HM J, Ng T-H, Chi GYH, Lipicky RJ. Testing for the existence of a dose combinationon beating its components. Am Stat Ass Proc Biopharmaceut Sect 1989: 53-9.
46. Carter WH, Gennings C, Staniswalis JG, Campbell ED, While KL. A statistical approach to the construction and analysis of isobolograms. J Am Coll Toxicol 1988; 7: 963-73.
47. Tsai C-M, Gazdar AF, Venzon DJ, et al. Lack of in vitro synergy between etoposide and cis-diammine-dichloro-platinum(II). Cancer Res 1989; 49: 2390-7.
48. Miaskowski C, Levine JD. Comments on the evaluation of drug interaction using isobolographic an analysis of variance. Pain 1992; 51: 383-7.